Board of Directors 

Robert Spiegel, MD, FACP
Chairman

Dr. Spiegel is a physician and oncologist with over 30 years of biopharma experience. At Schering-Plough he was Senior Vice President of Worldwide Clinical Research, prior to becoming Chief Medical Officer and Senior Vice President of Schering-Plough Research Institute in 1998, a position he held until his retirement from Schering-Plough in 2009. He has deep experience in clinical product development, has been involved in filing over 30 New Drug Applications, and has extensive familiarity with regulatory authorities in the U.S. and globally.   Dr. Spiegel currently serves as Chairman of the Board of the private company Vidac Pharma and is on the Board of Directors of the public companies Geron Corporation, Edge Therapeutics, and Sucampo Pharmaceuticals.  He is a venture advisor to the Israel Biotechnology Fund, Senior Advisor to Warburg Pincus as well as a consultant to various biopharma companies. He is also an Associate Professor at Weill Cornell Medical College. Earlier in his career, Dr. Spiegel was a Research Fellow at the NIH, National Cancer Institute and Assoc. Professor at NYU Cancer Center.

Scott Carmer
Chief Operating Officer, NexImmune

Mr. Carmer has 27 years of diverse leadership experience in the biopharmaceutical industry that spans activities from early stage clinical development through commercialization and sales. He joined NexImmune in early 2014 and currently serves as the company’s Chief Operating Officer with responsibility for corporate operations, strategy and product development. Before joining NexImmune, Mr. Carmer held senior level positions at AstraZeneca, MedImmune, Genentech, Amgen and GlaxoSmithKline. Most recently, at AstraZeneca he led the US Specialty Care Division with responsibility for the company’s portfolio of oncology and infectious disease products. Prior to AstraZeneca, Mr. Carmer served as the Chief Commercial Officer at MedImmune. Mr. Carmer was also Vice President, Rheumatology Sales & Marketing for Genentech. Prior to Genentech, Mr. Carmer held several leadership roles of increasing responsibility at Amgen, including  Executive Director of Global Marketing. Mr. Carmer started his career at GlaxoSmithKline.

Tim Bertram, PhD
Dr. Bertram is the CEO of RegenMed (Cayman) Ltd, a regenerative medicine biotechnology company developing cell-based products with the potential to transform the treatment of kidney diseases leading to renal failure.  He currently serves on the Board of Directors for multiple biotechnology companies. As CEO he lead RegenMed Therapeutics from start-up, through organizational building and acquisition.  He has been involved in biotechnology company operations for over 10 years.  During his 20-year career in large pharma, he held technical leadership and executive roles at Pfizer, SmithKline Beecham Pharmaceuticals, and Procter & Gamble Co.  Dr. Bertram has taken small and large molecules, biomaterials and cell based technologies from discovery into clinical development supporting commercialization of products in multiple therapeutic areas. He has been directly involved with the development of 8 commercial medical products in multiple jurisdictions and has over 175 scientific publications supporting over 25 commercially-relevant patents.  Dr. Bertram has held multiple academic appointments and industrial advisory positions at leading US and European educational institutions.

Graham Burton, MBBS, MRCS, LRCP
Dr. Burton is a physician with more than 25 years of successful experience in global regulatory practice in the biotechnology and pharmaceutical industries. He currently serves as a consultant to several biotechnology and pharmaceutical companies in the area of regulatory affairs. During his career he served for many years at Celgene Corporation and Johnson & Johnson where held key executive management positions in international regulatory development, strategic partnering with marketing and clinical development and helped lead the successful completion of multiple global New Drug Applications.  From 2003-2013, Dr. Burton served as Senior Vice President, Regulatory Affairs, Pharmacovigilance and Corporate Compliance and Celgene, a role in which he fostered strong relationships with global regulatory agencies and managed the Celgene Drug Safety Pharmacovigilence Worldwide department.  Prior to that he was a Senior Vice President, Global Regulatory Affairs & Quality Assurance at Johnson & Johnson Pharmaceutical Research & Development. Earlier in his career, Dr. Burton was a Senior Medical Officer in the UK Department of Health.

Paul D'Angio, RPh, MSJ
Mr. D’Angio is an advisor to several biotechnology and pharmaceutical companies and has been in the pharmaceutical industry for more than 30 years, with experience in commercial manufacturing, drug product development, risk management operations and investigational materials supply. From 1998 to 2016 he served as Senior Vice President, Global Head ofTechnical Operations at Celgene Corporation where he gained extensive cross-functional and technical leadership experience in building and operating a global pharmaceutical manufacturing and supply chain organization. He provided direct leadership in establishing global commercial readiness standards and practices at Celgene, resulting in a number of timely CMC filing and rapid product launches. Mr. D’Angio has a particular commitment to operational excellence and expertise in the management of highly technical cross-functional international teams focused on asset development through filing and commercialization. He has also built teams with long standing and industry leading employee engagement metrics. Earlier in his career, Mr D’Angio served for 13 years in the manufacturing group at Novartis.

Alan S. Roemer, MBA, MPH
Mr. Roemer is the Senior Vice President, Corporate Development and a founding senior leadership team member of Roivant Sciences, a biopharmaceutical company focused on reducing the time and cost of developing new medicines for patients and sharing those savings with the healthcare system. He previously served as Roivant’s Senior Vice President, Finance & Operations and has raised approximately $1.2 billion in private and public (IPO) capital for Roivant, Axovant Sciences and Myovant Sciences since 2014. Prior to joining Roivant, Mr. Roemer was a Managing Director for the Trout Group and Trout Capital, where he provided financial advisory and investor relations services for life sciences companies and completed over $300 million of fundraising transactions. He previously served as Chief Financial Officer & Treasurer of Zelos Therapeutics and was a Vice President & General Manager and the first full-time management hire at Pharmasset (acquired by Gilead). Mr. Roemer was a healthcare consultant for Booz-Allen & Hamilton and Deloitte Consulting, and he held various operational roles at Bank of America. Mr. Roemer currently serves on the Board of Trustees of the Helene Fuld College of Nursing.

Zhengbin (Bing) Yao, Ph.D.
Dr. Yao is the Senior Vice President, R&D and Head of Respiratory, Inflammation & Autoimmunity at MedImmune and leads a cross-functional team dedicated to therapeutic area strategy, prioritization and advancement of the company’s RIA portfolio, a position he has held since 2010.  He is an accomplished executive and scientist with more than 20 years of experience in the biotechnology and pharmaceutical industry. At MedImmune, he initiated the MEDI-Wuxi joint venture and currently serves the CEO. Dr. Yao also co-chairs the MedI/AstraZeneca-Amgen collaboration.  Prior to joining MedImmune, Dr. Yao led the project team leaders (PTL) group for immunology, neurosciences, virology and metabolism for Genentech and prior to that served as Vice President of Research, acting head of Clinical, and Corporate Officer for Tanox. Earlier in his career Dr. Yao held key roles at Aventis and Amgen. Dr. Yao has authored more than 50 peer reviewed publications and holds over 20 patents and patent applications.